Cover Image
市場調查報告書

流感疫苗的收益預測及R&D展望 2016-2026年:包含三價、四價流感疫苗接種的技術預測

Influenza Vaccine Revenue Forecasts and R&D Outlook 2016-2026: Prospects for Technologies Including Trivalent and Quadrivalent Flu Shots

出版商 Visiongain Ltd 商品編碼 349913
出版日期 內容資訊 英文 139 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
流感疫苗的收益預測及R&D展望 2016-2026年:包含三價、四價流感疫苗接種的技術預測 Influenza Vaccine Revenue Forecasts and R&D Outlook 2016-2026: Prospects for Technologies Including Trivalent and Quadrivalent Flu Shots
出版日期: 2016年01月13日 內容資訊: 英文 139 Pages
簡介

全球流感疫苗收益,預計2018年達到64億美元。由於技術進步及需求擴大,預計銷售額從2016年到2026年將上升。

本報告提供全球流感疫苗市場相關調查,兒童、成人用流感疫苗的現在、未來的開發趨勢,包含疫苗輸送技術的研究開發的進步,疫苗疫苗接種上政府、國際組織所扮演的角色,包含影響醫療提供者的供需趨勢,主要已發展的市場、新興市場分析,產業的SWOT分析、STEP分析,及主要流感疫苗的收益預測等彙整,為您概述為以下內容。

第1章 調查概要

第2章 全球流感疫苗市場:簡介

  • 流感是什麼,以及在全球對健康來說有多嚴重?
  • 社會、經濟上的負擔是什麼?
  • 流感病毒
  • 傳染病或全球性流行的發生?
  • 流感疫苗市場主要影響因素

第3章 全球流感疫苗市場展望

  • 全球流感市場實際成果
  • 全球流感疫苗市場收益預測
  • 全球流感市場:產業趨勢

第4章 流感疫苗的次市場:展望

  • 三價流感疫苗
  • 四價流感疫苗

第5章 主要流感疫苗:收益預測

  • Fluzone/Vaxigrip (IIV4):銷售額預測、議論
  • Afluria/Fluvax (IIV3):銷售額預測、議論
  • Fluarix/FluLaval:銷售額預測、議論
  • FluMist/Fluenz (LAIV4):銷售額預測、議論
  • Fluvirin (IIV3) / Flucelvax (ccIIV3) :銷售額預測、議論
  • FluBlok (RIV3):銷售額預測、議論
  • 其他疫苗:銷售額預測、議論

第6章 主要已發展市場的流感疫苗市場

  • 流感疫苗:主要市場
  • 美國的疫苗市場
  • 日本的流感疫苗市場
  • 英國的流感疫苗市場
  • 德國的流感疫苗市場
  • 法國的流感疫苗市場
  • 義大利的流感疫苗市場
  • 西班牙的流感疫苗市場

第7章 主要新興市場上流感疫苗

  • 流感疫苗:主要市場
  • 中國的流感疫苗市場
  • 印度的流感疫苗市場
  • 巴西的流感疫苗市場
  • 俄羅斯的流感疫苗市場

第8章 流感疫苗的研發產品線

  • 正在開發的季節性流感疫苗
  • 正在開發的通用流感疫苗 (萬能流感疫苗)

第9章 全球流感疫苗產業、市場定性分析

  • SWOT分析
  • STEP分析

第10章 調查採訪

第11章 結論

  • 利用了流感疫苗接種的流感的預防日益重要
  • 正在在全球流感疫苗市場中成長消費者的日本
  • 巴西及印度表示大幅度的成長
  • 萬能流感疫苗的登場
  • 美國維持優勢
  • 結論

圖表

目錄
Product Code: PHA0084

Influenza Vaccines - Your 2016 Guide to Developments and Sales Potentials

Do you want to explore the future of vaccines against the influenza virus? If so, visiongain's new report shows you trends, R&D, sales results, opportunities and revenue forecasts.

Avoid missing out. With our research and analysis you assess companies, technologies and products, benefiting your reputation for commercial insight.

Read on to explore the flu shots industry and see what revenue its market could generate in future.

Sales prospects of human flu preventions - our study shows you what is possible

Our new study gives revenue predictions at overall world, submarket, product and national levels. You gain discussions and expert opinion on vaccines protecting against influenza:

  • Influenza vaccine revenues to 2026 - discover the overall potential of that market worldwide, seeing commercial opportunities and possibilities
  • 2 submarkets' revenues to 2026 - explore that industry's segments at world level, finding the most lucrative and promising technologies and trends
  • 6 revenue forecasts covering leading vaccine brands to 2026 - see how those anti-flu agents can compete and succeed, discovering their sales potentials
  • 11 leading countries' revenue forecasts to 2026 - investigate countries in the Americas, Europe and Asia, assessing prospects for influenza market expansion
  • Analysis of leading companies and R&D pipelines for that preventive medicine - assess potentials of companies, seeing how they can compete and succeed
  • Assessment of what stimulates and restrains that important healthcare market - analyse challenges, strengths and views, seeing how you can gain.

Forecasting of that world market, showing what is possible for those prophylactic medicines

In our 138 page report you receive 32 tables, 32 charts and an interview with a vaccine producer. Besides giving revenue predictions, our new analysis shows you recent results, business news, sales growth rates, market shares and R&D trends.

First our study gives revenue forecasts to 2026 for two influenza submarkets:

  • Trivalent vaccines
  • Quadrivalent vaccines.

With our report you investigate influenza vaccine development, manufacturing and selling. You also explore potential shifts in market shares from 2016 to 2026. See what leading companies do, assessing that industry's potential.

Product forecasts - assess sales potentials of leading brands

Our new analysis also shows you predictions for leading flu vaccines, giving six revenue forecasts to 2026:

  • Fluzone/Vaxigrip
  • Afluria/Fluvax
  • Fluarix/FluLaval
  • FluMist/Fluenz
  • Fluvirin/Flucelvax
  • FluBlok.

With our investigation you assess business potentials for leading influenza vaccines. You also explore research and development. Discover what is possible from 2016, then, benefiting your influence and reputation for commercial insight.

image1

image2

National markets for influenza vaccine sales - what does the future hold?

Our study shows you prospects for influenza vaccine revenues in developed and developing countries. There see individual forecasts to 2026 for 11 countries:

  • United States
  • Japan
  • Germany, France, United Kingdom, Italy and Spain (the EU5 group)
  • Brazil, Russia, India and China (the BRIC group).

With our analysis you investigate countries with highest revenues, demand and potential sales growth. Explore progress, needs and opportunities, seeing how you can gain.

image3

image4

Forces affecting developers, producers and sellers of those healthcare products

Our report explains issues, trends, events and R&D from 2016, including these forces:

  • Paediatric and adult influenza vaccines - present and future developments
  • Advances in research and development, including vaccine delivery technology - assess innovations, progress and opportunities
  • Deals in that industry, including the creation of Seqirus in July 2015
  • Antigenic drift and shift - overcoming viral challenges to protect populations
  • Seasonal influenza epidemics and pandemic outbreaks giving high demand.

Also explore the effects of these influences:

  • Governments and international organisations' roles in flu vaccination
  • Supply and demand, including effects of healthcare providers and payers' policies
  • US healthcare reforms - benefits for vaccine sales
  • Strengths, weaknesses, opportunities and threats, as well as social, technological, economic and political forces - examine what influences that industry
  • Potential for universal flu vaccine to transform the market - see what is possible.

Worldwide revenues of influenza vaccines will reach $6.4 billion in 2018, our study predicts. Sales will rise from 2016 to 2026 as technological advances and rising demand give growth opportunities. With our analysis you see what the future holds and how you can benefit.

Influenza vaccines - who are the top companies?

From 2016, large pharmaceutical companies and other biopharma specialists can prosper in that important healthcare market. Discover how, seeing organisations' potentials.

In particular our study explores these industry leaders:

  • Sanofi Pasteur
  • GSK
  • Novartis
  • AstraZeneca
  • CSL and Seqirus
  • Protein Sciences Corporation.

Gain predictions for influenza vaccines, getting information to help you stay ahead

With our independent study you assess products, companies, progress and potentials. Explore commercial opportunities and technological advances. Discover what is possible.

Having that information means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how to save time and effort, also benefiting your plans, decisions, presentations, proposals and influence.

Try our new study. That investigation shows you data, trends, opportunities and forecasts for that expanding vaccine market. So avoid missing out - please get our report here now.

Table of Contents

1. Report Overview

  • 1.1 Global Influenza Vaccine Market Overview
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by This Analytical Study
  • 1.5 Who is This Report For?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2. Introduction to the World Influenza Vaccines Market

  • 2.1 What is Influenza and How Serious is it to Health Worldwide?
  • 2.2 What is the Social and Economic Burden?
  • 2.3 The Influenza Virus
    • 2.3.1 Antigenic Drift
    • 2.3.2 Antigenic Shift
  • 2.4 An Epidemic or a Pandemic Outbreak?
    • 2.4.1 Seasonal Influenza Epidemic
    • 2.4.2 Pandemic Influenza
  • 2.5 Key Influencers of the Influenza Vaccine Market
    • 2.5.1 Governments and International Organisations
      • 2.5.1.1 The World Health Organization (WHO)
      • 2.5.1.2 Governmental Influence
    • 2.5.2 Leading Manufacturers
      • 2.5.2.1 Sanofi Pasteur
      • 2.5.2.2 GSK
      • 2.5.2.3 Novartis
      • 2.5.2.4 AstraZeneca

3. Influenza Vaccine World Market Outlook, 2016-2026

  • 3.1 The World Influenza Market Performance 2014
    • 3.1.1 Growing Elderly Population
    • 3.1.2 Paediatric Influenza Vaccines - High Demand
    • 3.1.3 Emerging Markets
  • 3.2 The World Influenza Market Revenue Forecast, 2015-2026
  • 3.3 The World Influenza Market: Industry Trends, 2016-2026
    • 3.3.1 Demand Driven Trends
    • 3.3.2 Supply
    • 3.3.3 Funding Trends
    • 3.3.4 Protecting the Workforce of an Economy

4. Influenza Vaccine Submarkets: Prospects, 2016-2026

  • 4.1 Trivalent Influenza Vaccines
    • 4.1.1 Trivalent Vaccines: Revenue Forecast to 2026
  • 4.2 Quadrivalent Vaccines
    • 4.2.1 Quadrivalent Vaccines: Revenue Forecast to 2026

5. Leading Influenza Vaccines: Revenue Predictions, 2016-2026

  • 5.1 Fluzone/Vaxigrip (IIV4) - Sales Forecasting and Discussion 2015-2026
  • 5.2 Afluria/Fluvax (IIV3) - Sales Forecasting and Discussion 2015-2026
  • 5.3 Fluarix/FluLaval - Sales Forecasting and Discussion 2015-2026
  • 5.4 FluMist/Fluenz (LAIV4) - Sales Forecasting and Discussion 2015-2026
  • 5.5 Fluvirin (IIV3) / Flucelvax (ccIIV3) - Sales Forecasting and Discussion 2015-2026
  • 5.6 FluBlok (RIV3) - Sales Forecasting and Discussion 2015-2026
  • 5.7 Other Vaccines: Sales Forecasting and Discussion 2015-2026

6. Influenza Vaccines in Leading Developed Markets, 2016-2026

  • 6.1 Influenza Vaccines: Leading Markets, 2014, 2020, 2026
    • 6.1.1 Influenza Vaccine: Leading Developed Markets
  • 6.2 The US Vaccine Market: 2016-2026
    • 6.2.1 The US Vaccine Market: 2015
    • 6.2.2 The US Vaccine Market Forecast: 2015-2026
    • 6.2.3 Obama Healthcare Reform - Benefits for Vaccine Sales
  • 6.3 The Japanese Influenza Vaccine Market 2016-2026
    • 6.3.1 The Japanese Vaccine Market: 2015
    • 6.3.2 The Japanese Vaccine Market Forecast: 2015-2026
    • 6.3.3 Filing the Vaccine Gap
  • 6.4 The United Kingdom Influenza Vaccine Market 2016-2026
    • 6.4.1 The UK Vaccine Market: 2015
    • 6.4.2 The UK Vaccine Market: 2015-2026
  • 6.5 The German Influenza Vaccine Market: 2016-2026
    • 6.5.1 The German Vaccine Market: 2015
    • 6.5.2 The German Vaccine Market Forecast: 2015-2026
  • 6.6 The French Influenza Vaccine Market 2016-2026
    • 6.6.1 The French Vaccine Market: 2015
    • 6.6.2 The French Vaccine Market Forecast: 2015-2026
    • 6.6.3 French Healthcare System - Events, Policies and Effects
  • 6.7 The Italian Influenza Vaccine Market: 2016-2026
    • 6.7.1 The Italian Vaccine Market: 2015
    • 6.7.2 The Italian Vaccine Market Forecast: 2015-2026
    • 6.7.3 Uncertain Foundation - Challenges in Public Healthcare
  • 6.8 The Spanish Influenza Vaccine Market 2016-2026
    • 6.8.1 The Spanish Vaccine Market: 2015
    • 6.8.2 The Spanish Vaccine Market Forecast: 2015-2026
    • 6.8.3 District Rules - Economic Challenges

7. Influenza Vaccines in Leading Emerging Markets, 2016-2026

  • 7.1 Influenza Vaccines: Leading Markets, 2014, 2020, 2026
    • 7.1.1 Influenza Vaccine: Leading Emerging National Markets
  • 7.2 The Chinese Influenza Vaccine Market: 2016-2026
    • 7.2.1 The Chinese Influenza Vaccine Market: 2015
    • 7.2.2 The Chinese Influenza Vaccine Market Forecast: 2015-2026
    • 7.2.3 High National Demand for Influenza Vaccines
  • 7.3 The Indian Influenza Vaccine Market: 2016-2026
    • 7.3.1 The Indian Vaccine Market: 2015
    • 7.3.2 The Indian Influenza Vaccine Market Forecast: 2015-2026
    • 7.3.3 Complications of Influenza Vaccines - How Much Progress Possible?
  • 7.4 The Brazilian Influenza Vaccine Market: 2016-2026
    • 7.4.1 The Brazilian Vaccine Market: 2015
    • 7.4.2 The Brazilian Vaccine Market Forecast: 2015-2026
  • 7.5 The Russian Vaccine Market: 2016-2026
    • 7.5.1 The Russian Vaccine Market: 2015
    • 7.5.2 The Russian Vaccine Market Forecast: 2015-2026
    • 7.5.3 Power of the State

8. R&D Pipeline for Flu Vaccines

  • 8.1 Seasonal Influenza Vaccines in Development
    • 8.1.1 Sanofi Pasteur
      • 8.1.1.1 FLUZONE Quadrivalent
      • 8.1.1.2 VaxiGrip QIV IM Quadrivalent
    • 8.1.2 bioCSL
      • 8.1.2.1 Quadrivalent Paediatric Influenza Vaccine
    • 8.1.3 Novartis
      • 8.1.3.1 Cell Culture Quadrivalent Intramuscular Vaccine
      • 8.1.3.2 Quadrivalent Paediatric Intramuscular Vaccine
      • 8.1.3.3 Fluad Vaccine
      • 8.1.3.4 Flucelvax Intramuscular Vaccine
    • 8.1.4 Takeda Pharmaceuticals
    • 8.1.4.1 TAK850 Influenza Vaccine
  • 8.2 Universal Influenza Vaccines in Development

9. Qualitative Analysis of the World Influenza Vaccines Industry and Market, 2016-2026

  • 9.1 SWOT Analysis of the World Influenza Vaccines Industry and Market, 2016
    • 9.1.1 Strengths
      • 9.1.1.1 Ageing Population
      • 9.1.1.2 Influenza Prevention is Crucial
      • 9.1.1.3 Sales Growth in Emerging National Markets
      • 9.1.1.4 Rising Awareness of the Disease
    • 9.1.2 Weaknesses
      • 9.1.2.1 Supply Chain Costs
      • 9.1.2.2 Time Pressure
      • 9.1.2.3 Barriers to Market Entry
    • 9.1.3 Opportunities
      • 9.1.3.1 Strong Research and Development Pipeline
      • 9.1.3.2 Vaccine Delivery - Innovations and Opportunities for Improvements
      • 9.1.3.3 Universal Flu Vaccine
      • 9.1.3.4 Adult Vaccines - High Need
    • 9.1.4 Threats
      • 9.1.4.1 Productivity Gap
  • 9.2 STEP Analysis of the World Influenza Vaccines Industry and Market, 2016
    • 9.2.1 Social Factors
      • 9.2.1.1 Creating a Healthier Society
      • 9.2.1.2 Public Fears of Side-Effects
    • 9.2.2 Technological Forces
      • 9.2.2.1 Advancements in Vaccine Technology
    • 9.2.3 Economic Factors
      • 9.2.3.1 Cost and Time Restraints
      • 9.2.3.2 Emerging Markets Create Demand
    • 9.2.4 Political Factors
      • 9.2.4.1 Influence of Governments

10. Research Interview

  • 10.1 Interview with BiondVax Pharmaceuticals, 2013
    • 10.1.1 Progress of BiondVax's Candidate Vaccine
    • 10.1.2 Trialling the Vaccine as a Primer
    • 10.1.3 Assays for Universal Vaccine Effectiveness
    • 10.1.4 Key Differentiators for BiondVax's Candidate

11. Conclusions

  • 11.1 Prevention of Influenza by Use of Flu Shots Rises in Importance
  • 11.2 Japan as a Rising Consumer in the World Influenza Vaccine Market
  • 11.3 Brazil and India Show Robust Growth
  • 11.4 Emergence of a Universal Flu Vaccine
  • 11.5 The US to Retain its Dominance
  • 11.6 Concluding Remarks

List of Tables

  • Table 1.1 Selected National Vaccines Markets: Revenues ($m) and Market Shares (%) by Leading Country, 2014, 2020 and 2026
  • Table 3.1 Overall World Influenza Vaccine Market: Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2015-2026
  • Table 4.1 Influenza Vaccines Sub-Markets: Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2015-2026
  • Table 4.2 The Trivalent Influenza Vaccines Submarket: Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2015-2026
  • Table 4.3 The Quadrivalent Influenza Vaccines Submarket: Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2015-2026
  • Table 5.1 Leading Influenza Vaccines: Revenues ($m), 2014
  • Table 5.2 Fluzone/Vaxigrip: Revenue ($m), 2012-2014
  • Table 5.3 Fluzone/Vaxigrip: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026
  • Table 5.4 Afluria/Fluvax: Revenue ($m), 2013-2014
  • Table 5.5 Afluria/Fluvax: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026
  • Table 5.6 Fluarix/FluLaval: Revenue ($m), 2012-2014
  • Table 5.7 Fluarix/FluLaval: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026
  • Table 5.8 FluMist/Fluenz: Revenue ($m), 2012-2014
  • Table 5.9 FluMist/Fluenz: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026
  • Table 5.10 Fluvirin/Flucelvax Revenue ($m), 2013-2014
  • Table 5.11 Fluvirin/Flucelvax: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026
  • Table 5.12 FluBlok Revenue ($m), 2013-2014
  • Table 5.13 FluBlok: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026
  • Table 5.14 Other Influenza Vaccines Forecast: ($m), Annual Growth ($m), CAGR (%), 2015-2026
  • Table 6.1 Influenza Vaccines Market Revenues ($m) and Market Shares (%) by Leading Country, 2014, 2020 and 2026
  • Table 6.2 The US Influenza Vaccine Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026
  • Table 6.3 The Japanese Influenza Vaccine Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026
  • Table 6.4 The UK Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 6.5 The German Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 6.6 The French Human Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 6.7 The Italian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 6.8 The Spanish Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 7.1 Human Vaccines Market Revenues ($m) and Market Shares (%) by Leading Country, 2014, 2020 and 2026
  • Table 7.2 The Chinese Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 7.3 The Indian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 7.4 The Brazilian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 7.5 The Russian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 8.1 Seasonal Influenza Vaccines in Development, 2015
  • Table 8.2 Universal Influenza Vaccines in Development, 2015

List of Figures

  • Figure 1.1 Influenza Vaccines Market Segmentation
  • Figure 3.1 Influenza Vaccines Market Shares (%), 2014
  • Figure 3.2 Growth in the Uptake of Influenza Vaccine, 1990-2015
  • Figure 3.3 Influenza Vaccines: Segmentation by Age (%), 2014
  • Figure 3.4 Time of Last Influenza Shot by Age, 2015
  • Figure 3.5 Influenza Vaccines: Market Share by Geographical Segmentation, 2015
  • Figure 3.6 World Influenza Vaccines Market: Drivers and Restraints, 2016-2026
  • Figure 4.1 Influenza Vaccines: Main Submarket Segmentation (%), 2014
  • Figure 4.2 Influenza Vaccines: Submarkets Shift in Market Share (%), 2014-2026
  • Figure 5.1 Fluzone/Vaxigrip: Revenue Forecast ($m), 2015-2026
  • Figure 5.2 Afluria/Fluvax: Revenue Forecast ($m), 2015-2026
  • Figure 5.3 Fluarix/FluLaval: Revenue Forecast ($m), 2015-2026
  • Figure 5.4 FluMist/Fluenz: Revenue Forecast ($m), 2015-2026
  • Figure 5.5 Fluvirin/Flucelvax: Revenue Forecast ($m), 2015-2026
  • Figure 5.6 FluBlok: Revenue Forecast ($m), 2015-2026
  • Figure 5.7 Other Influenza Vaccines: Revenue Forecast ($m), 2015-2026
  • Figure 6.1 Influenza Vaccine Market Share (%): Leading National Markets, 2014
  • Figure 6.2 Developed National Markets: Drivers and Restraints, 2016-2026
  • Figure 6.3 The US Influenza Vaccine Revenue Forecast ($m), 2015-2026
  • Figure 6.4 The Japanese Influenza Vaccine Revenue Forecast ($m), 2015-2026
  • Figure 6.5 The UK Influenza Vaccines Revenue Forecast ($m), 2015-2026
  • Figure 6.6 The German Influenza Vaccines Revenue Forecast ($m), 2015-2026
  • Figure 6.7 The French Influenza Vaccines Revenue Forecast ($m), 2015-2026
  • Figure 6.8 The Italian Influenza Vaccines Revenue Forecast ($m), 2015-2026
  • Figure 6.9 The Spanish Influenza Vaccines Revenue Forecast ($m), 2015-2026
  • Figure 7.1 Emerging National Markets: Drivers and Restraints, 2016-2026
  • Figure 7.2 The Chinese Influenza Vaccines Revenue Forecast ($m), 2015-2026
  • Figure 7.3 The Indian Influenza Vaccines Revenue Forecast ($m), 2015-2026
  • Figure 7.4 The Brazilian Influenza Vaccines Revenue Forecast ($m), 2015-2026
  • Figure 7.5 The Russian Influenza Vaccines Revenue Forecast ($m), 2015-2026
  • Figure 9.1 SWOT Analysis of the Influenza Vaccines Market, 2016
  • Figure 9.2 STEP Analysis of the Influenza Vaccines Market, 2016

Companies Listed

  • Advisory Committee for Immunization Practices
  • Astellas Pharmaceuticals
  • AstraZeneca
  • Bharat Immunologicals and Biologicals Corporation Limited
  • Binnopharm
  • bioCSL
  • BioManguinhos/Oswaldo Cruz Foundation
  • BiondVax
  • BiondVax
  • Bionor
  • Brazilian Ministry of Health
  • Butantan Institute
  • Center for Biologics Evaluation and Research
  • Centre for Disease Control and Prevention
  • China National Biotech Group
  • China's National Regulatory Authority
  • Chinese Food and Drug Administration
  • CSL
  • CureVac
  • Daiichi Sankyo
  • Dynavax
  • Flanders Institute
  • Food and Drug Administration (FDA)
  • FORT
  • Fresenius Pharmaceuticals
  • Gamma Vaccines
  • Gavi Alliance
  • GlaxoSmithKline (GSK)
  • Global Influenza Programme
  • Grippol
  • Health Service Bureau, Japan
  • Immune Targeting Systems
  • Indian Association of Paediatrics
  • Janssen Pharmaceuticals
  • Jenner Institute, University of Oxford
  • Johnson & Johnson
  • Krka Pharmaceuticals
  • Medicago
  • Medicare
  • MedImmune
  • Merck
  • MSD Pharmaceuticals
  • National Health Service, UK
  • Novartis
  • Organisation for Economic Co-operation and Development
  • Panacea Biotech
  • Partnership for Influenza Vaccine Introduction
  • Petrovax
  • Pfizer
  • Protein Sciences Corporation
  • Sanofi Pasteur
  • Seqirus
  • Servizio Sanitario Nationale
  • Shionogi Pharmaceuticals
  • Sistema Unico de Saude
  • SmithKline Beecham
  • Takeda Pharmaceuticals
  • Terumo Pharmaceuticals
  • The Ministry of Health, Labour and Welfare, Japan
  • The Scripps Research Institute
  • Ultriks
  • US Department of Health and Human Services
  • VaxInnate
  • WHO Strategic Advisory Group of Experts
  • World Health Organization (WHO)
Back to Top